Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001088875-25-000027
Filing Date
2025-02-12
Accepted
2025-02-12 10:52:00
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5831
  Complete submission text file 0001088875-25-000027.txt   7540
Mailing Address CALTON SQUARE 1 GREENSIDE ROW EDINBURGH X0 EH13AN
Business Address CALTON SQUARE 1 GREENSIDE ROW EDINBURGH X0 EH13AN 00441312752000
BAILLIE GIFFORD & CO (Filed by) CIK: 0001088875 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0
Type: SCHEDULE 13G/A

Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Subject) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90223 | Film No.: 25613053
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)